12 articles
A comprehensive review reveals mitochondrial quality control failures precede kidney damage in diabetes, spotlighting emerging drug targets.
New mouse study reveals CD38, not viral replication itself, depletes brain NAD+ during Zika infection — pointing to a druggable target.
Blocking CD38 with compound 78c replenishes NAD+, slashes inflammatory cytokines, and reduces oxidative stress in old macrophages infected with oral pathogens.
A landmark review reveals how declining NAD+ levels and disrupted circadian clocks form a vicious cycle driving dementia progression.
New research reveals how blocking CD38 boosts NAD+ levels, protecting retinal cells and offering a fresh therapeutic angle on glaucoma.
A comprehensive review reveals how the enzyme CD38 drives cardiovascular and neurological disease through calcium, NAD+, and inflammation signaling.
CD38 activity rises with age, depleting NAD+ and accelerating tissue decline. New research positions CD38 inhibitors as promising anti-aging therapeutics.
A new vaccination strategy targeting CD38 improved physical function, cognition, metabolism, and NAD+ levels in aging mice — with just a few injections.
A macrophage subset with high CD38 expression accelerates AKI-to-CKD progression by depleting NAD+, triggering tubular cell senescence and fibrosis.
A Harvard small molecule screen identified apigenin as a CD38 inhibitor, revealing how this common flavonoid raises cellular NAD levels.
Combining CD38 and PD-1 inhibitors produced durable remissions in relapsed NK/T-cell lymphoma, with median response duration exceeding 29 months.
A selective CD38 inhibitor restores blood-brain barrier integrity and improves cognition in a mouse model of vascular dementia.
